Ivantis Raises $27M For Eye Treatments
Ivantis has raised $27 million in a first closing of its Series B round, led by Ascension Health Ventures. Return investors New Enterprise Associates and Delphi Ventures, as well as new investors including MemorialCare Innovation Fund also participated in the round. Ivantis is focused on new technologies to treat eye disease.
1 February 2013•4 mins read
